Sign inJoin waitlistJoin the waitlist

Clint Allen

Acting Chief, Surgical Oncology Program · Clinical Center at the National Institutes of Health

Credentials: · · · · ·

History

Surgical Oncology Program Division · Clinical Center at the National Institutes of Health
Present
University of Houston
Present

University of Washington-Seattle Campus
2012–2013
Otolaryngology - Head and Neck Surgery
Washington University/B-JH/SLCH Consortium
2007–2012
Texas A&M School of Medicine

Research

Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Clinical Cancer Research · 2020 · Last of 13 authors · Corresponding · 250 citations
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
JCI Insight · 2019 · Last of 15 authors · 217 citations
Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ
Cancer Research · 2017 · Last of 9 authors · Corresponding · 190 citations

CW
Carter Van Waes
36 papers
James Gulley
20 papers
Scott Norberg
11 papers · 1 as a fellow
Nyall London
10 papers · 8 as a resident
Ravindra Uppaluri
10 papers
Jason Redman
8 papers
Christian Hinrichs
7 papers
PS
Patrick Soon-Shiong
7 papers
Ruth Davis
7 papers · 4 as a resident
Wojciech Mydlarz
7 papers
Albert Merati
6 papers
Gary Gallia
6 papers

Grants

Characterization and Enhancement of Anti-Tumor Immune Responses in Head and Neck Cancer
National Institute on Deafness and Other Communication Disorders · ZIA
Contact PI · $13.5M · National Institute on Deafness and Other Communication Disorders
Enhancing Anti-Tumor Immunity in Head and Neck Neoplasms
National Cancer Institute · ZIA
Contact PI · $13.4M · Division of Basic Sciences - Nci
NIDCD Core for Clinical Research and Care
National Institute on Deafness and Other Communication Disorders · ZID
Contact PI · $2.8M · National Institute on Deafness and Other Communication Disorders

Clinical trials

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
Principal investigator · Terminated
National Institute on Deafness and Other Communication Disorders (NIDCD)
2020–2023
Biospecimen Procurement for Head and Neck Disorders
Principal investigator · Recruiting
National Cancer Institute (NCI)
2018–2029